Editas Medicine Inc (EDIT) COO Alexandra Glucksmann Sells 1000 Shares

Modesto Morganelli
Marzo 21, 2017

Shares of Editas Medicine Inc (NASDAQ:EDIT) traded up 0.49% during trading on Monday, reaching $22.41. The offering is slated to close on March 22, 2017, subject to customary closing conditions. Editas Medicine shares last traded at $22.30, with a volume of 6,602,246 shares traded.

Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell. The shares were sold at an average price of $26.41, for a total value of $26,410.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

On Wednesday, February 15th, Alexandra Glucksmann sold 6,000 shares of Editas Medicine stock. The shares were sold at an average price of $19.20, for a total transaction of $288,000.00. Following the completion of the transaction, the chief financial officer now owns 15,000 shares in the company, valued at approximately $288,000. The disclosure for this sale can be found here.

A number of research analysts have recently weighed in on EDIT shares. Editas Medicine, Inc. (NASDAQ:EDIT) has returns on equity of -56.10%, which is measuring a corporation's profitability by revealing how much profit generates by EDIT with the shareholders' money.

According to Yahoo Finance, the price target for the company which analysts are aiming is 40. JPMorgan Chase & Co. reaffirmed a "hold" rating on shares of Editas Medicine in a research note on Sunday, February 19th. Finally, Cowen and Company restated a "buy" rating on shares of Editas Medicine in a report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The 1-year price target of the company is 33.5.

Currently, the company has SMA200 (200-day simple moving average) of 12.07 Percent. The firm's market cap is $799.23 million.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Friday, March 3rd. (EDIT) reported its EPS in the last quarter as $-1.1/Share lagging the analyst estimate of $-0.62/Share by the difference of $-0.48. Equities research analysts anticipate that Editas Medicine Inc will post ($2.85) EPS for the current fiscal year.

Analysts estimated $-0.62/share for the previous Quarter, where Editas Medicine Inc. Russell Investments Group Ltd. purchased a new position in Editas Medicine during the fourth quarter worth $284,000. EcoR1 Capital LLC purchased a new stake in Editas Medicine during the fourth quarter worth $10,172,000. Finally, Highland Capital Management LP acquired a new stake in shares of Editas Medicine during the fourth quarter worth about $1,460,000. Hedge funds and other institutional investors own 60.89% of the company's stock.

The agreement states that Allergan will have full access and licensing options for up to five of Editas's genome-editing ocular programs. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE